Survival and desferrioxamine in thalassaemia major
- PMID: 6802413
- PMCID: PMC1497956
- DOI: 10.1136/bmj.284.6322.1081
Survival and desferrioxamine in thalassaemia major
Abstract
A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical